12(S)-hydroxyeicosatrienoic acid (12(S)-HETrE) compounds and compositions comprising the same are disclosed. Methods of using the compounds in the prevention and treatment of thrombosis and thrombotic disorders are also disclosed.

The present invention relates to compounds of formula (I): ##STR00001##
in which R1 is a hydrogen atom, a phenyl radical, or a straight or branched, saturated or unsaturated hydrocarbon radical having 1 to 8 carbon atoms.

The present invention relates to compounds of formula (I): ##STR00001##
in which R1 is a hydrogen atom, a phenyl radical, or a straight or branched, saturated or unsaturated hydrocarbon radical having 1 to 8 carbon atoms.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, ##STR00001##
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer.

Novel rexinoid compounds are provided herein. Also provided herein are methods of using the compounds to treat disorders, such as metabolic disorders, diabetes, insulin resistance, glucose intolerance, obesity, steatosis, inflammation, and/or cancer.

Processes for producing 2,5-dichlorophenol and 3,6-dichloro-2-methoxybenzoic acid are described. Various processes for isomerizing 2,4-dichlorophenol over a zeolite catalyst to form 2,5-dichlorophenol are provided. Processes for preparing 2,5-dichlorophenol including hydroxylating 1,4-dichlorobenzene are also described. The present invention also relates to processes for producing 3,6-dichloro-2-methoxybenzoic acid.

Processes for producing 2,5-dichlorophenol and 3,6-dichloro-2-methoxybenzoic acid are described. Various processes for isomerizing 2,4-dichlorophenol over a zeolite catalyst to form 2,5-dichlorophenol are provided. Processes for preparing 2,5-dichlorophenol including hydroxylating 1,4-dichlorobenzene are also described. The present invention also relates to processes for producing 3,6-dichloro-2-methoxybenzoic acid.

The invention relates to a compound according to formula I wherein when R.sub.5 is H, and R.sub.1 and R.sub.2 form a ring system, then said compound is selected from the following compounds of formula II or formula IV or when R.sub.2 is H, and R.sub.1 and R.sub.5 form a ring system, then said compound has formula III

##STR00001##